Figure 1.
Proportion of patients with toxicities by antimetabolite DI in the entire cohort (A) and MEMS subcohort (B).

Proportion of patients with toxicities by antimetabolite DI in the entire cohort (A) and MEMS subcohort (B).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal